MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET - PubMed (original) (raw)
. 2004 Dec 28;63(12):2332-40.
doi: 10.1212/01.wnl.0000147469.18313.3b.
D Perani, S Sorbi, K Herholz, B Nacmias, V Holthoff, E Salmon, J-C Baron, M T R De Cristofaro, A Padovani, B Borroni, M Franceschi, L Bracco, A Pupi
Affiliations
- PMID: 15623696
- DOI: 10.1212/01.wnl.0000147469.18313.3b
MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET
L Mosconi et al. Neurology. 2004.
Abstract
Objectives: To investigate whether the combination of fluoro-2-deoxy-d-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD).
Method: After 1 year, 8 of 37 patients with MCI converted to AD (22%). Differences in baseline regional glucose metabolic rate (rCMRglc) across groups were assessed on a voxel-based basis using a two-factor analysis of variance with outcome (converters [n = 8] vs nonconverters [n = 29]) and APOE genotype (E4 carriers [E4+] [n = 16] vs noncarriers [E4-] [n = 21]) as grouping factors. Results were considered significant at p < 0.05, corrected for multiple comparisons.
Results: All converters showed reduced rCMRglc in the inferior parietal cortex (IPC) as compared with the nonconverters. Hypometabolism in AD-typical regions, that is, temporoparietal and posterior cingulate cortex, was found for the E4+ as compared with the E4- patients, with the E4+/converters (n = 5) having additional rCMRglc reductions within frontal areas, such as the anterior cingulate (ACC) and inferior frontal (IFC) cortex. For the whole MCI sample, IPC rCMRglc predicted conversion to AD with 84% overall diagnostic accuracy (p = 0.003). Moreover, ACC and IFC rCMRglc improved prediction for the E4+ group, yielding 100% sensitivity, 90% specificity, and 94% accuracy (p < 0.0005), thus leading to an excellent discrimination.
Conclusion: Fluoro-2-deoxy-d-glucose-PET measures may improve prediction of the conversion to Alzheimer disease, especially in combination with the APOE genotype.
Similar articles
- Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease.
Mosconi L, Nacmias B, Sorbi S, De Cristofaro MT, Fayazz M, Tedde A, Bracco L, Herholz K, Pupi A. Mosconi L, et al. J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):370-6. doi: 10.1136/jnnp.2003.014993. J Neurol Neurosurg Psychiatry. 2004. PMID: 14966149 Free PMC article. - 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
Knopman DS, Jack CR Jr, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC. Knopman DS, et al. Neurobiol Aging. 2014 Sep;35(9):2096-106. doi: 10.1016/j.neurobiolaging.2014.03.006. Epub 2014 Mar 11. Neurobiol Aging. 2014. PMID: 24702820 Free PMC article. - Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A. Drzezga A, et al. J Nucl Med. 2005 Oct;46(10):1625-32. J Nucl Med. 2005. PMID: 16204712 Clinical Trial. - Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.
Mosconi L, Herholz K, Prohovnik I, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Sorbi S, Pupi A. Mosconi L, et al. J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):15-23. doi: 10.1136/jnnp.2003.030882. J Neurol Neurosurg Psychiatry. 2005. PMID: 15607989 Free PMC article. - Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L. Mosconi L. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510. doi: 10.1007/s00259-005-1762-7. Eur J Nucl Med Mol Imaging. 2005. PMID: 15747152 Review.
Cited by
- Prognostic model for predicting Alzheimer's disease conversion using functional connectome manifolds.
Kim S, Kim M, Lee JE, Park BY, Park H. Kim S, et al. Alzheimers Res Ther. 2024 Oct 9;16(1):217. doi: 10.1186/s13195-024-01589-3. Alzheimers Res Ther. 2024. PMID: 39385241 Free PMC article. - Predicting conversion from mild cognitive impairment to Alzheimer's disease: a multimodal approach.
Agostinho D, Simões M, Castelo-Branco M. Agostinho D, et al. Brain Commun. 2024 Jun 14;6(4):fcae208. doi: 10.1093/braincomms/fcae208. eCollection 2024. Brain Commun. 2024. PMID: 38961871 Free PMC article. - Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients.
Yang Z, Cummings JL, Kinney JW, Cordes D; Alzheimer’s Disease Neuroimaging Initiative. Yang Z, et al. Front Neurosci. 2023 Apr 14;17:1151820. doi: 10.3389/fnins.2023.1151820. eCollection 2023. Front Neurosci. 2023. PMID: 37123373 Free PMC article. - Prediction of conversion to dementia using interpretable machine learning in patients with amnestic mild cognitive impairment.
Chun MY, Park CJ, Kim J, Jeong JH, Jang H, Kim K, Seo SW. Chun MY, et al. Front Aging Neurosci. 2022 Aug 5;14:898940. doi: 10.3389/fnagi.2022.898940. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35992586 Free PMC article. - Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.
Jett S, Malviya N, Schelbaum E, Jang G, Jahan E, Clancy K, Hristov H, Pahlajani S, Niotis K, Loeb-Zeitlin S, Havryliuk Y, Isaacson R, Brinton RD, Mosconi L. Jett S, et al. Front Aging Neurosci. 2022 Mar 9;14:831807. doi: 10.3389/fnagi.2022.831807. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35356299 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous